Government life sciences advisor, Chris Brinsmead, visited Manchester on Friday 13 January, to gain insight into the city’s leading life sciences and biomedical sector.
His visit was coordinated by Manchester Science Parks (MSP) with support from MIDAS, Bionow and the NHS. Chris has over thirty years experience in the Pharmaceutical industry, with previous roles as the president of the ABPI, and as president of AstraZeneca UK. He is currently the chairman of the UK Life Science Marketing Board.
The visit to Manchester included a detailed overview of the biomedical industry in the region followed by a working lunch and round-table discussion with representatives from life sciences companies including Phagenesis and QIAGEN.
Chris also visited the Central Manchester University Hospitals NHS Foundation Clinical Campus, and Icon Development Solutions’ Clinical Trials Unit.
Speaking of his visit, Brinsmead said: “Manchester is a centre of excellence for life sciences and is a part of one of the UK’s top three biomedical regions – the North West. Therefore, today’s visit has been an incredibly important opportunity to learn and understand more about the developments that are currently taking place.
“It is clear that Manchester has plenty to offer, with exciting projects in the pipeline such as the Medipark at the Airport City Enterprise Zone, the redevelopment of the Former Royal Eye Hospital and the ongoing development of the many research centres which populate the Corridor on Oxford Road.
“Manchester demonstrates that it has the capacity for growth in terms of jobs creation and investment in the life sciences sector building on the many companies and projects which are already based in the region.”
“I will be ensuring that its many innovative hubs, such as the University of Manchester; commercial facilities such as Manchester Science Parks; and the region’s NHS organisations, continue to be acknowledged at a strategic level within government.”
Tim Newns, chief executive of MIDAS, said: “Chris is a keen ambassador for Manchester; he recognises the importance of the life sciences and biomedical sector to the region and is doing everything that he can to champion the UK as a location for life science activity and Manchester as a key centre.”
“There are over 280 biomedical companies in the North West region, employing more than 22,000 people. Our infrastructure includes world-class academic institutions such as the University of Manchester and dedicated centres such as Manchester Science Parks.
“Coupled with the strong working partnerships that are currently in place between MIDAS ,UKTI and Bionow, I’m confident that we can ensure the region retains a prominent role in life sciences, and that we’re well-equipped to nurture international investment from this important field.”